ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2137

Critical Role of Fibroblast-like Synoviocytes Glycolytic Metabolism in Rheumatoid Arthritis

Ricard Garcia-Carbonell1, Ajit Divakaruni1, Alessia Lodi2, Ildefonso Vicente-Suarez3, Hilde Cheroutre4, Gerry Boss1, Arindam Saha1, Stefano Tiziani5, Anne Murphy6, Gary S. Firestein7 and Monica Guma6, 1University of California, San Diego, La Jolla, CA, 2nutritional Sciences, University of Texas at Austin, Austin, TX, 3LIAI, La Jolla, CA, 4Autoimmune Research, LIAI, La Jolla, CA, 5Nutritional Sciences, University of Texas at Austin, Austin, TX, 6Pharmacology, University of California, San Diego, La Jolla, CA, 7Division of Rheumatology, Allergy and Immunology, University of California, San Diego, La Jolla, CA

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Animal models, Fibroblasts, metabolism and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 9, 2015

Title: Rheumatoid Arthritis - Human Etiology and Pathogenesis II

Session Type: ACR Concurrent Abstract Session

Session Time: 4:30PM-6:00PM

 

Background/Purpose: Glucose metabolism is altered not only in tumor cell growth but also in immune cells on activation. However, little is known about glucose metabolism in fibroblast-like synoviocytes (FLS). We recently showed that a glycolysis inhibitor suppressed the aggressive behavior of cultured RA FLS, including proliferation, cytokine secretion and cell migration. Here, we further evaluated changes in glucose metabolism in both RA synovium and RA FLS and its role in inflammation and joint damage.

Methods: The glucose metabolism profile of synovium was determined by 1H-MRS. Analysis of FLS oxygen consumption/extracellular acidification was determined by Seahorse technology. Effect of inflammatory mediators on the glycolytic rate in FLS was determined by Seahorse after LPS and PDGF stimulation. Glucose metabolism related gene expression was determined by qPCR. The increase of glycolysis in a murine model was determined using IRDye®800CW 2-DG, a fluorescent optical imaging agent that assesses glucose uptake, and by FACS. For arthritis experiments, the glycolysis inhibitor bromopyruvate (BrPa; 5mg/kg) was injected daily i.p. at the peak of arthritis in two murine models, passive K/BxN model (from day 5) and collagen induced arthritis (from day 35).

Results: Compared to osteoarthritis (OA), RA FLS had a higher baseline glycolytic rate, a decreased mitochondrial respiration and increased extracellular acidification after LPS stimulation. Intracellular lactate was also higher in RA synovium and several metabolites related to glucose metabolism correlated with lactate levels, suggesting higher glucose metabolism in RA synovium samples. Glucose transporter 1 (GLUT1) expression correlated with FLS baseline functions and her expression increased after LPS and PDGF stimulation. In a mouse model of inflammatory arthritis, we observed an increase of glucose uptake in arthritic joints and an increase of glucose uptake and glycolytic gene expression in the CD45-PDPN+ stromal cell compartment. Glycolytic inhibition by BrPa administered in vivo significantly decreased arthritis severity in both animal models.

Conclusion: Targeting metabolic dysfunction offers a novel approach of understanding the mechanisms of disease and potential new treatments. Glycolytic inhibition may directly modulate synoviocyte-mediated inflammatory functions and could be an effective treatment strategy for arthritis.


Disclosure: R. Garcia-Carbonell, None; A. Divakaruni, None; A. Lodi, None; I. Vicente-Suarez, None; H. Cheroutre, None; G. Boss, None; A. Saha, None; S. Tiziani, None; A. Murphy, None; G. S. Firestein, None; M. Guma, None.

To cite this abstract in AMA style:

Garcia-Carbonell R, Divakaruni A, Lodi A, Vicente-Suarez I, Cheroutre H, Boss G, Saha A, Tiziani S, Murphy A, Firestein GS, Guma M. Critical Role of Fibroblast-like Synoviocytes Glycolytic Metabolism in Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/critical-role-of-fibroblast-like-synoviocytes-glycolytic-metabolism-in-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/critical-role-of-fibroblast-like-synoviocytes-glycolytic-metabolism-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology